Breaking boundaries: Innovating the future of hepatitis B and D treatment together
Thomas Berg (Moderator), Larry Blatt (Aligos representative), Todd Correll (VIR representative), Susan Dixon (GSK representative), Simon Fletcher (Gilead representative)
This EASL Studio is supported by Aligos Therapeutics, Gilead, GSK and VIR Biotechnology.
ℹ️ Please click here to access the podcast version of this EASL Studio episode.